Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine.

Literature DB >> 32229574

News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine.

Lynne Peeples.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2020 PMID： 32229574 PMCID： PMC7165470 DOI： 10.1073/pnas.2005456117

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

× No keyword cloud information.

5 in total

1. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.

Authors: Meagan Bolles; Damon Deming; Kristin Long; Sudhakar Agnihothram; Alan Whitmore; Martin Ferris; William Funkhouser; Lisa Gralinski; Allison Totura; Mark Heise; Ralph S Baric
Journal: J Virol Date: 2011-09-21 Impact factor: 5.103

Review 2. Immune enhancement of viral infection.

Authors: S B Halstead
Journal: Prog Allergy Date: 1982

3. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization.

Authors: H Vennema; R J de Groot; D A Harbour; M Dalderup; T Gruffydd-Jones; M C Horzinek; W J Spaan
Journal: J Virol Date: 1990-03 Impact factor: 5.103

Review 4. Antibody-dependent enhancement of virus infection and disease.

Authors: Sol M Cancel Tirado; Kyoung-Jin Yoon
Journal: Viral Immunol Date: 2003 Impact factor: 2.257

Review 5. Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease.

Authors: Patricio L Acosta; Mauricio T Caballero; Fernando P Polack
Journal: Clin Vaccine Immunol Date: 2015-12-16

5 in total

58 in total

Review 1. Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Authors: Nina Butkovich; Enya Li; Aaron Ramirez; Amanda M Burkhardt; Szu-Wen Wang
Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2020-11-08

Review 2. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.

Authors: Jimin Xu; Yu Xue; Richard Zhou; Pei-Yong Shi; Hongmin Li; Jia Zhou
Journal: Med Res Rev Date: 2020-12-05 Impact factor: 12.944

Review 3. Addressing the global surge of COVID-19 cases: Insights from diagnostics, improved treatment strategies, vaccine development and application.

Authors: Kamoru A Adedokun; Ayodeji O Olarinmoye; Lawal O Olayemi; Muhammed R Shehu; Jelili O Mustapha; Ramat T Kamorudeen; Sulaimon A Nassar
Journal: J Clin Transl Res Date: 2021-03-12

4. Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers.

Authors: Belinda M Jackson-Thompson; Emilie Goguet; Eric D Laing; Cara H Olsen; Simon Pollett; K Monique Hollis-Perry; Santina E Maiolatesi; Luca Illinik; Kathleen F Ramsey; Anatalio E Reyes; Yolanda Alcorta; Mimi A Wong; Julian Davies; Orlando Ortega; Edward Parmelee; Alyssa R Lindrose; Matthew Moser; Elizabeth Graydon; Andrew G Letizia; Christopher A Duplessis; Anuradha Ganesan; Kathleen P Pratt; Allison M Malloy; David W Scott; Stephen K Anderson; Andrew L Snow; Clifton L Dalgard; John H Powers; David Tribble; Timothy H Burgess; Christopher C Broder; Edward Mitre
Journal: BMC Infect Dis Date: 2021-06-09 Impact factor: 3.090

5. Pulmonary stromal expansion and intra-alveolar coagulation are primary causes of COVID-19 death.

Authors: Laszlo Szekely; Bela Bozoky; Matyas Bendek; Masih Ostad; Pablo Lavignasse; Lars Haag; Jieyu Wu; Xu Jing; Soham Gupta; Elisa Saccon; Anders Sönnerborg; Yihai Cao; Mikael Björnstedt; Attila Szakos
Journal: Heliyon Date: 2021-05-24

Review 6. COVID-19 vaccines and nanomedicine.

Authors: Robert S Shapiro
Journal: Int J Dermatol Date: 2021-06-05 Impact factor: 3.204

Review 7. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.

Authors: Idris Nasir Abdullahi; Anthony Uchenna Emeribe; Hafeez Aderinsayo Adekola; Sharafudeen Dahiru Abubakar; Amos Dangana; Halima Ali Shuwa; Sunday Theophilus Nwoba; Jelili Olaide Mustapha; Muyideen Titilope Haruna; Kafayat Adepeju Olowookere; Olawale Sunday Animasaun; Charles Egede Ugwu; Solomon Oloche Onoja; Abdullahi Sani Gadama; Musa Mohammed; Isa Muhammad Daneji; Dele Ohinoyi Amadu; Peter Elisha Ghamba; Nkechi Blessing Onukegbe; Muhammad Sagir Shehu; Chiladi Isomah; Adamu Babayo; Abdurrahman El-Fulaty Ahmad
Journal: Hum Vaccin Immunother Date: 2020-09-16 Impact factor: 3.452

8. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target.

Authors: Bingqing Xia; Xurui Shen; Yang He; Xiaoyan Pan; Feng-Liang Liu; Yi Wang; Feipu Yang; Sui Fang; Yan Wu; Zilei Duan; Xiaoli Zuo; Zhuqing Xie; Xiangrui Jiang; Ling Xu; Hao Chi; Shuangqu Li; Qian Meng; Hu Zhou; Yubo Zhou; Xi Cheng; Xiaoming Xin; Lin Jin; Hai-Lin Zhang; Dan-Dan Yu; Ming-Hua Li; Xiao-Li Feng; Jiekai Chen; Hualiang Jiang; Gengfu Xiao; Yong-Tang Zheng; Lei-Ke Zhang; Jingshan Shen; Jia Li; Zhaobing Gao
Journal: Cell Res Date: 2021-06-10 Impact factor: 46.297

9. Is increased mortality by multiple exposures to COVID-19 an overseen factor when aiming for herd immunity?

Authors: Kristina Barbara Helle; Arlinda Sadiku; Girma Mesfin Zelleke; Toheeb Babatunde Ibrahim; Aliou Bouba; Henri Christian Tsoungui Obama; Vincent Appiah; Gideon Akumah Ngwa; Miranda Ijang Teboh-Ewungkem; Kristan Alexander Schneider
Journal: PLoS One Date: 2021-07-16 Impact factor: 3.240

10. Potential Biases Arising From Epidemic Dynamics in Observational Seroprotection Studies.

Authors: Rebecca Kahn; Lee Kennedy-Shaffer; Yonatan H Grad; James M Robins; Marc Lipsitch
Journal: Am J Epidemiol Date: 2021-02-01 Impact factor: 4.897